Prognostic Value of HER2 Protein Expression in PT1 GII-PT1 GIII Bladder Transitional Cell Carcinoma

Introduction and Objective: Our perspective study was designed to evaluate the prognostic value of HER2 protein expression in PT1 GII-PT1 GIII bladder transitional cell carcinoma (TCC).

Materials and Methods: From April 2002 to January 2006, a total of 84 specimen of (PT1grade2-PT1grade3) bladder transitional cell carcinoma were analyzed immunohistochimically (Hercep-Test). All histological removals were obtained from transurethral resection. Immunoreactivity was assessed considering average positivity of the tumour resection shavings.

Results: Overall, HER2 protein strong overexpression was detected in 30/42 of PT1grade3. It was a potential recurrence predictor factor in bladder TCC (PT1grade3). HER negative expression was noted in 26/40 of TCC (PT1grade2): they are still without progression after BCGtherapy. HER negative expression, in PT1grde2, was associated to tumours with less than O2 localization and without angiogenesis in all cases (26/40). HER negative expression was correlated to favourable out come: four recurrences in all (26 cases) with PT1grade2 during five years.

Conclusions: Evaluation of HER2 over expression, in PT1grade2 and PT1grade3, has been proven to be useful in predicting recurrence and progression. It seems to have potential application in this regard.